These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 30585770)

  • 21. Effectiveness of MiniMed 640G with SmartGuard® System for prevention of hypoglycemia in pediatric patients with type 1 diabetes mellitus.
    Villafuerte Quispe B; Martín Frías M; Roldán Martín MB; Yelmo Valverde R; Álvarez Gómez MÁ; Barrio Castellanos R
    Endocrinol Diabetes Nutr; 2017 Apr; 64(4):198-203. PubMed ID: 28417874
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of 6 months of hybrid closed-loop insulin delivery in adults with type 1 diabetes: a randomised controlled trial protocol.
    McAuley SA; de Bock MI; Sundararajan V; Lee MH; Paldus B; Ambler GR; Bach LA; Burt MG; Cameron FJ; Clarke PM; Cohen ND; Colman PG; Davis EA; Fairchild JM; Hendrieckx C; Holmes-Walker DJ; Horsburgh JC; Jenkins AJ; Kaye J; Keech AC; King BR; Kumareswaran K; MacIsaac RJ; McCallum RW; Nicholas JA; Sims C; Speight J; Stranks SN; Trawley S; Ward GM; Vogrin S; Jones TW; O'Neal DN
    BMJ Open; 2018 Jun; 8(6):e020274. PubMed ID: 29886443
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Study of MiniMed 640G Insulin Pump with SmartGuard in Prevention of Low Glucose Events in Adults with Type 1 Diabetes (SMILE): Design of a Hypoglycemia Prevention Trial with Continuous Glucose Monitoring Data as Outcomes.
    De Valk HW; Lablanche S; Bosi E; Choudhary P; Silva JD; Castaneda J; Vorrink L; De Portu S; Cohen O
    Diabetes Technol Ther; 2018 Nov; 20(11):758-766. PubMed ID: 30325656
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The psychosocial outcomes of advanced hybrid closed-loop system in children and adolescents with type 1 diabetes.
    Jalilova A; Pilan BŞ; Demir G; Özbaran B; Balkı HG; Arslan E; Köse SG; Özen S; Darcan Ş; Gökşen D
    Eur J Pediatr; 2024 Jul; 183(7):3095-3103. PubMed ID: 38661816
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and Performance of the Omnipod Hybrid Closed-Loop System in Adults, Adolescents, and Children with Type 1 Diabetes Over 5 Days Under Free-Living Conditions.
    Sherr JL; Buckingham BA; Forlenza GP; Galderisi A; Ekhlaspour L; Wadwa RP; Carria L; Hsu L; Berget C; Peyser TA; Lee JB; O'Connor J; Dumais B; Huyett LM; Layne JE; Ly TT
    Diabetes Technol Ther; 2020 Mar; 22(3):174-184. PubMed ID: 31596130
    [No Abstract]   [Full Text] [Related]  

  • 26. Efficacy and safety of advanced hybrid closed loop systems in children with type 1 diabetes younger than 6 years.
    Rapini N; Martino M; Arnaldi C; Deodati A; Anagnostopoulou L; Amodeo ME; Ciampalini P; Pampanini V; Lorubbio A; Tosini D; Cianfarani S; Schiaffini R
    Front Endocrinol (Lausanne); 2024; 15():1382920. PubMed ID: 38836230
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and Glycemic Outcomes During the MiniMed™ Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes.
    Carlson AL; Sherr JL; Shulman DI; Garg SK; Pop-Busui R; Bode BW; Lilenquist DR; Brazg RL; Kaiserman KB; Kipnes MS; Thrasher JR; Reed JHC; Slover RH; Philis-Tsimikas A; Christiansen M; Grosman B; Roy A; Vella M; Jonkers RAM; Chen X; Shin J; Cordero TL; Lee SW; Rhinehart AS; Vigersky RA
    Diabetes Technol Ther; 2022 Mar; 24(3):178-189. PubMed ID: 34694909
    [No Abstract]   [Full Text] [Related]  

  • 28. Effectiveness of Automated Insulin Management Features of the MiniMed
    Zhong A; Choudhary P; McMahon C; Agrawal P; Welsh JB; Cordero TL; Kaufman FR
    Diabetes Technol Ther; 2016 Oct; 18(10):657-663. PubMed ID: 27672710
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Six months of hybrid closed loop in the real-world: An evaluation of children and young adults using the 670G system.
    Berget C; Messer LH; Vigers T; Frohnert BI; Pyle L; Wadwa RP; Driscoll KA; Forlenza GP
    Pediatr Diabetes; 2020 Mar; 21(2):310-318. PubMed ID: 31837064
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improved Glycemia with Hybrid Closed-Loop Versus Continuous Subcutaneous Insulin Infusion Therapy: Results from a Randomized Controlled Trial.
    Garg SK; Grunberger G; Weinstock R; Lawson ML; Hirsch IB; DiMeglio LA; Pop-Busui R; Philis-Tsimikas A; Kipnes M; Liljenquist DR; Brazg RL; Kudva YC; Buckingham BA; McGill JB; Carlson AL; Criego AB; Christiansen MP; Kaiserman KB; Griffin KJ; Forlenza GP; Bode BW; Slover RH; Keiter A; Ling C; Marinos B; Cordero TL; Shin J; Lee SW; Rhinehart AS; Vigersky RA;
    Diabetes Technol Ther; 2023 Jan; 25(1):1-12. PubMed ID: 36472543
    [No Abstract]   [Full Text] [Related]  

  • 31. Reduction in Hypoglycemia With the Predictive Low-Glucose Management System: A Long-term Randomized Controlled Trial in Adolescents With Type 1 Diabetes.
    Abraham MB; Nicholas JA; Smith GJ; Fairchild JM; King BR; Ambler GR; Cameron FJ; Davis EA; Jones TW;
    Diabetes Care; 2018 Feb; 41(2):303-310. PubMed ID: 29191844
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glucose Control Using a Standard Versus an Enhanced Hybrid Closed Loop System: A Randomized Crossover Study.
    Paldus B; Lee MH; Jones HM; McAuley SA; Horsburgh JC; Roem KL; Ward GM; MacIsaac RJ; Cohen N; Colman PG; Jenkins AJ; O'Neal DN
    Diabetes Technol Ther; 2019 Jan; 21(1):56-58. PubMed ID: 30620641
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Six-Month Effectiveness of Advanced
    Tornese G; Buzzurro F; Carletti C; Faleschini E; Barbi E
    Front Endocrinol (Lausanne); 2021; 12():766314. PubMed ID: 34858339
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sustained Effectiveness of an Advanced Hybrid Closed-Loop System in a Cohort of Children and Adolescents With Type 1 Diabetes: A 1-Year Real-World Study.
    Passanisi S; Salzano G; Bombaci B; Minuto N; Bassi M; Bonfanti R; Scialabba F; Mozzillo E; Di Candia F; Monti S; Graziani V; Maffeis C; Piona CA; Arnaldi C; Tosini D; Felappi B; Roppolo R; Zanfardino A; Delvecchio M; Lo Presti D; Calzi E; Ripoli C; Franceschi R; Reinstadler P; Rabbone I; Maltoni G; Alibrandi A; Zucchini S; Marigliano M; Lombardo F;
    Diabetes Care; 2024 Jun; 47(6):1084-1091. PubMed ID: 38626260
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Randomized Trial of Closed-Loop Control in Children with Type 1 Diabetes.
    Breton MD; Kanapka LG; Beck RW; Ekhlaspour L; Forlenza GP; Cengiz E; Schoelwer M; Ruedy KJ; Jost E; Carria L; Emory E; Hsu LJ; Oliveri M; Kollman CC; Dokken BB; Weinzimer SA; DeBoer MD; Buckingham BA; Cherñavvsky D; Wadwa RP;
    N Engl J Med; 2020 Aug; 383(9):836-845. PubMed ID: 32846062
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prospective Analysis of the Impact of Commercialized Hybrid Closed-Loop System on Glycemic Control, Glycemic Variability, and Patient-Related Outcomes in Children and Adults: A Focus on Superiority Over Predictive Low-Glucose Suspend Technology.
    Beato-Víbora PI; Gallego-Gamero F; Lázaro-Martín L; Romero-Pérez MDM; Arroyo-Díez FJ
    Diabetes Technol Ther; 2020 Dec; 22(12):912-919. PubMed ID: 31855446
    [No Abstract]   [Full Text] [Related]  

  • 37. MiniMed 780G™ in 2- to 6-Year-Old Children: Safety and Clinical Outcomes After the First 12 Weeks.
    Pulkkinen MA; Varimo TJ; Hakonen ET; Harsunen MH; Hyvönen ME; Janér JN; Kiiveri SM; Laakkonen HM; Laakso SM; Wehkalampi K; Hero MT; Miettinen PJ; Tuomaala AK
    Diabetes Technol Ther; 2023 Feb; 25(2):100-107. PubMed ID: 36511831
    [No Abstract]   [Full Text] [Related]  

  • 38. Cost-Effectiveness of Hybrid Closed Loop Insulin Pumps Versus Multiple Daily Injections Plus Intermittently Scanned Glucose Monitoring in People With Type 1 Diabetes in The Netherlands.
    Serné EH; Roze S; Buompensiere MI; Valentine WJ; De Portu S; de Valk HW
    Adv Ther; 2022 Apr; 39(4):1844-1856. PubMed ID: 35226346
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison of the usage of an open-source automated insulin delivery system and the MiniMed™ 780 G system in children and adolescents with type 1 diabetes in real-world settings: the AWeSoMe study group.
    Landau Z; Lebenthal Y; Mazor-Aronovitch K; Brener A; Levek N; Jacobi-Polishook T; Ben Ari T; Abiri S; Haim A; Nir J; Rachmiel M; Pinhas-Hamiel O
    Endocrine; 2024 Jun; 84(3):943-950. PubMed ID: 38225516
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glycemic Outcomes Persist for up to 2 Years in Very Young Children with the Omnipod
    DeSalvo DJ; Bode BW; Forlenza GP; Laffel LM; Buckingham BA; Criego AB; Schoelwer M; MacLeish SA; Sherr JL; Hansen DW; Ly TT
    Diabetes Technol Ther; 2024 Jun; 26(6):383-393. PubMed ID: 38277156
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.